| 1. |
- Djekic, Demir, 1989-, et al.
(författare)
-
Metabolomics in atherosclerosis
- 2015
-
Ingår i: International Journal of Cardiology Metabolic & Endocrine. - : Elsevier. - 2214-7624. ; 8, s. 26-30
-
Forskningsöversikt (refereegranskat)abstract
- It is well established that atherosclerotic cardiovascular disease (ACD) is a leading cause of death in the West. There are several predisposing factors for ACD, which can be divided into two groups: firstly modifiable risk factors, including hypertension, dyslipidaemia, type 2 diabetes mellitus, obesity, smoking and a sedentary lifestyle and secondly the unmodifiable risk factors such as age, gender and heredity. Since single biomarkers are unable to provide sufficient information about the biochemical pathways responsible for the disease, there is a need for a holistic approach technology, e.g. metabolomics, that provide sufficiently detailed information about the metabolic status and assay results will be able to guide food, drug and lifestyle optimisation. Rather than investigating a single pathway, metabolomics deal with the integrated identification of biological and pathological molecular pathways. Mass spectrometry (MS) and nuclear magnetic resonance (NMR) spectroscopy are the two most commonly used techniques for metabolite profiling. This detailed review concluded that metabolomics investigations seem to have great potential in identifying small groups of disturbed metabolites which if put together should draw various metabolic routs that lead to the common track pathophysiology. The current evidence in using metabolomics in atherosclerotic cardiovascular disease is also limited and morewell designed studies remain to be established, which might significantly improve the comprehension of atherosclerosis pathophysiology and consequently management.
|
|
| 2. |
- Karlson, Björn W., 1953, et al.
(författare)
-
Achievement of combined goals of low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol with three different statins: Results from VOYAGER
- 2014
-
Ingår i: IJC Metabolic and Endocrine. - : Elsevier Ireland Ltd. - 2214-7624. ; 5, s. 61-66
-
Tidskriftsartikel (refereegranskat)abstract
- Background: Guidelines suggest that the combination of low-density lipoprotein cholesterol (LDL-C) and non-high-density lipoprotein cholesterol (non-HDL-C) is the most clinically relevant goal for lipid-lowering treatments. Methods: Data from VOYAGER, an individual patient data meta-analysis including 32,258 patients from 37 clinical trials, was used to determine the percentage of patients reaching combined goals of LDL-C and non-HDL-C following treatment with simvastatin, atorvastatin, or rosuvastatin. Paired comparisons were made between each dose of rosuvastatin and the same or higher doses of simvastatin and atorvastatin. Results: Each dose of rosuvastatin brought significantly more patients to the combined goal of LDL-C <. 100. mg/dL and non-HDL-C <. 130. mg/dL than the same or double dose of atorvastatin; atorvastatin 80. mg was significantly superior to rosuvastatin 10. mg (all p. <. 0.001). Each dose of rosuvastatin helped significantly more patients reach the combined goal than any dose of simvastatin (all p. <. 0.001), except for rosuvastatin 10. mg versus simvastatin 80. mg (non-significant). Also, each dose of rosuvastatin helped significantly more patients to reach the combined goal of LDL-C <. 70. mg/dL and non-HDL-C <. 100. mg/dL than the same or double dose of atorvastatin (all p. <. 0.001). Every dose of rosuvastatin was significantly superior to all doses of simvastatin (all p. ≤. 0.020), except for rosuvastatin 10. mg versus simvastatin 40. mg and 80. mg (non-significant). Conclusions: Physicians' choice of statin and dose is important in helping patients achieve the combined LDL-C and non-HDL-C goals recommended in established guidelines.
|
|
| 3. |
- Quintana, H. K., et al.
(författare)
-
Diabetes, hypertension, overweight and hyperlipidemia and 7-day case-fatality in first myocardial infarction
- 2016
-
Ingår i: International Journal of Cardiology Metabolic & Endocrine. - : ELSEVIER SCI LTD. - 2214-7624. ; 12, s. 30-35
-
Tidskriftsartikel (refereegranskat)abstract
- Background: Out-of-hospital deaths due to a first myocardial infarction (MI) are frequent and a big challenge for prevention. Increased knowledge about factors influencing MI fatality is needed. Metabolic risk factors have been studied in relation to MI fatality in-hospital but studies considering also out-of-hospital deaths are few. Aim: To assess howdiabetes and other metabolic risk factors associate with death within 7 days after first time MI among subjects aged between 45 and 70 identified in Stockholm County 1992-1994. Methods: Data were collected using questionnaires (close relatives of fatal cases were asked to fill the questionnaire), physical examinations, national registers and autopsy reports. Risk ratios (RR) of 7-day MI fatality with 95% confidence intervals (CI) associated with the risk factors under study were calculated using binomial regression with log link. Results: Out of 1905 first time MI cases included, 524 died within 7 days. After adjustments for age, sex, current smoking, education and general comorbidity, diabetes, but not hypertension and hyperlipidemia, was associated with MI fatality (RR 1.68, 95% CI 1.20-2.28). Overweight, as compared to normal BMI, was inversely associated with MI fatality (multiple adjusted RR 0.68, 95% CI 0.49-0.94); obesity results pointed in the samedirection (multiple adjusted RR 0.79, 0.52-1.16). Conclusions: In this population-based inception cohort study, diabetes but not hypertension and hyperlipidemia were associated with MI fatality. This further emphasizes the importance of diabetes as a cardiovascular risk factor and the need for close surveillance of diabetic patients. Overweight was however associated with decreased MI fatality.
|
|
